Why did reported EPS grow so much year-over-year?

Much of the increase reflects a lower acquired IPR&D charge. Q3 2024 included $2.83 billion in IPR&D (about $3.08 per share), compared with $655.7 million (about $0.71 per share) in Q3 2025. Underlying operating growth was also strong, with revenue up 54% and operating income up to $7.37 billion from $1.53 billion.

How sustainable is the growth from Mounjaro and Zepbound?

Demand is strong, but the company relies heavily on a few incretin products. U.S. pricing declined in the high single digits excluding a prior-period base effect, and realized prices fell 10% overall. Sustained growth depends on continued volume gains offsetting pricing pressure and competition.

What changed in full-year 2025 guidance?

Revenue guidance rose by $3.0 billion at the midpoint to $63.0–$63.5 billion, reflecting underlying performance and foreign exchange. Reported EPS guidance rose to $21.80–$22.50 and non-GAAP EPS guidance to $23.00–$23.70. Guidance includes $2.57 per share of IPR&D charges through Q3 but excludes any future IPR&D, so additional deals could lower reported EPS.

What are the main risks flagged in the release?

Key risks include pricing pressure and government policy, pending tariffs on pharmaceuticals (not reflected in guidance), a $364.9 million special charge in Q3 mainly tied to litigation, the non-deductible nature of acquired IPR&D affecting tax rates, and the usual pipeline, regulatory, manufacturing, and competitive uncertainties.

What does the pipeline and manufacturing news signal?

Positive Phase 3 orforglipron data and planned global obesity filings by year-end could extend Lilly's incretin leadership into oral dosing. New facilities in Virginia and Texas and the Puerto Rico expansion indicate heavy capacity investment to meet demand, which supports future revenue but adds to capital spending and fixed costs.

LLY 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed October 30, 2025. Cited figures are marked; the original filing is the authoritative source.

Eli Lilly reported third-quarter 2025 results on October 30, 2025 that were well ahead of the prior year, with revenue up 54% year-over-year to $17.60 billion^a, driven by a 62% increase in volume partially offset by a 10% decline in realized prices.

Growth was led by the incretin franchise: Mounjaro revenue rose 109% to $6.52 billion^b and U.S. Zepbound revenue rose about 184% to $3.57 billion. Reported EPS was $6.21 (versus $1.07 a year earlier) and non-GAAP EPS was $7.02. Gross margin expanded to 82.9% on a reported basis, helped by favorable product mix.

Comparisons are flattered by a large acquired IPR&D charge of $2.83 billion^c in Q3 2024 versus $655.7 million in Q3 2025, which tilts the year-over-year EPS comparison. Management raised full-year 2025 guidance. Revenue is now expected at $63.0 to $63.5 billion (from $60.0 to $62.0 billion), reported EPS at $21.80 to $22.50 and non-GAAP EPS at $23.00 to $23.70.

The company notes that guidance includes $2.57^d per share of acquired IPR&D charges incurred through Q3 and excludes any future IPR&D, so further business development charges could reduce reported results. Guidance also reflects the existing tariff environment and does not account for potential pharmaceutical sector tariffs. The filing also mentions a $364.9 million special charge in Q3 2025, primarily litigation-related, and a $350.3 million U.S. tax law change impact.

On the pipeline and operations side, Lilly reported positive results in four Phase 3 trials of orforglipron across type 2 diabetes and obesity, with global obesity submissions planned by year-end 2025. The FDA approved Inluriyo (imlunestrant) for certain breast cancer patients.

Lilly also announced new manufacturing investments in Virginia and Texas and an expansion in Puerto Rico. Investors should note that the filing is a furnished (not filed) 8-K under Item 2.02, and that the results rely heavily on a small number of incretin products.

02—Key points

Key Highlights

Q3 2025 revenue rose 54% year-over-year to $17.60 billion, driven by a 62% volume increase, partly offset by a 10% decline in realized prices.
Mounjaro revenue grew 109% to $6.52 billion and U.S. Zepbound revenue grew roughly 184% to $3.57 billion, underscoring incretin demand.
Reported EPS was $6.21 versus $1.07 a year earlier; non-GAAP EPS was $7.02 versus $1.18. The prior-year quarter included a $3.08 per share acquired IPR&D charge.
Reported gross margin rose to 82.9% of revenue (up 1.9 percentage points), mainly on favorable product mix.
2025 revenue guidance raised to $63.0–$63.5 billion from $60.0–$62.0 billion; reported EPS guidance raised to $21.80–$22.50 and non-GAAP EPS to $23.00–$23.70.
Orforglipron posted positive results in four Phase 3 trials, with global obesity regulatory submissions planned by end of 2025.
Guidance excludes IPR&D incurred after Q3 2025 and does not reflect potential pharmaceutical tariffs, both of which are key risks to watch.

03—Questions

Frequently Asked Questions

Why did reported EPS grow so much year-over-year?
Much of the increase reflects a lower acquired IPR&D charge. Q3 2024 included $2.83 billion in IPR&D (about $3.08 per share), compared with $655.7 million (about $0.71 per share) in Q3 2025. Underlying operating growth was also strong, with revenue up 54% and operating income up to $7.37 billion from $1.53 billion.
How sustainable is the growth from Mounjaro and Zepbound?
Demand is strong, but the company relies heavily on a few incretin products. U.S. pricing declined in the high single digits excluding a prior-period base effect, and realized prices fell 10% overall. Sustained growth depends on continued volume gains offsetting pricing pressure and competition.
What changed in full-year 2025 guidance?
Revenue guidance rose by $3.0 billion at the midpoint to $63.0–$63.5 billion, reflecting underlying performance and foreign exchange. Reported EPS guidance rose to $21.80–$22.50 and non-GAAP EPS guidance to $23.00–$23.70. Guidance includes $2.57 per share of IPR&D charges through Q3 but excludes any future IPR&D, so additional deals could lower reported EPS.
What are the main risks flagged in the release?
Key risks include pricing pressure and government policy, pending tariffs on pharmaceuticals (not reflected in guidance), a $364.9 million special charge in Q3 mainly tied to litigation, the non-deductible nature of acquired IPR&D affecting tax rates, and the usual pipeline, regulatory, manufacturing, and competitive uncertainties.
What does the pipeline and manufacturing news signal?
Positive Phase 3 orforglipron data and planned global obesity filings by year-end could extend Lilly's incretin leadership into oral dosing. New facilities in Virginia and Texas and the Puerto Rico expansion indicate heavy capacity investment to meet demand, which supports future revenue but adds to capital spending and fixed costs.

04—Continue

← View all 8-K filings